OTCMKTS:SPHRY

Starpharma Stock Forecast, Price & News

$15.00

-1.30 (-7.98 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$14.07

Now: $15.00▼

$15.00

50-Day Range

$13.72

MA: $15.74▼

$17.88

52-Week Range

$5.90

Now: $15.00▼

$19.87

Volume759 shs

Average Volume3,811 shs

Market Capitalization$609.03 million

P/E RatioN/A

Dividend YieldN/A

Beta1.86

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:SPHRY

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.starpharma.com

Phone61-3-8532-2700

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.03

Current Ratio5.48

Quick Ratio5.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.40 million

Price / Sales138.42

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.56 per share

Price / Book26.79

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares40,602,000

Market Cap$609.03 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Critical Survey: Starpharma (OTCMKTS:SPHRY) vs. PPD (NASDAQ:PPD)
March 31, 2021 | americanbankingnews.com

Starpharma Holdings Limited (OTCMKTS:SPHRY) Short Interest Update
March 27, 2021 | americanbankingnews.com

Starpharma (ASX:SPL) share price pushes higher on COVID-19 nasal spray update
March 25, 2021 | msn.com

Starpharma Up With News, Down With None; Timing Entry Makes Sense
February 27, 2021 | seekingalpha.com

Here’s why the Starpharma (ASX:SPL) share price just stormed to a record high
February 11, 2021 | msn.com

Why the Starpharma (ASX:SPL) share price hit a record high today
February 8, 2021 | msn.com

Starpharma (ASX:SPL) share price dips despite positive update
December 21, 2020 | msn.com

Our Take On Starpharma Holdings' (ASX:SPL) CEO Salary
December 3, 2020 | finance.yahoo.com

Why the Starpharma (ASX:SPL) share price is racing higher today
November 19, 2020 | fool.com.au

Will COVID Disappear Soon Or Do Investors Need To Pay Attention?
November 4, 2020 | seekingalpha.com

Starpharma raises $48.9 million to accelerate development of dendrimer product
October 30, 2020 | proactiveinvestors.com.hk

Starpharma Holdings Limited's (ASX:SPL) Path To Profitability
October 29, 2020 | finance.yahoo.com

Are Investors Undervaluing Starpharma Holdings Limited (ASX:SPL) By 39%?
September 23, 2020 | finance.yahoo.com

Starpharma’s COVID-19 nasal spray shows positive effect against COVID-19
September 14, 2020 | seekingalpha.com

The Starpharma share price jumps on new partnership deal
August 17, 2020 | msn.com

A Neglected Treatment Space For COVID-19
August 6, 2020 | seekingalpha.com

What Type Of Shareholders Own The Most Number of Starpharma Holdings Limited (ASX:SPL) Shares?
July 28, 2020 | finance.yahoo.com

Is Starpharma Holdings Limited's (ASX:SPL) CEO Overpaid Relative To Its Peers?
May 5, 2020 | finance.yahoo.com

Starpharma's SPL7013 Antiviral Takes On COVID-19
May 4, 2020 | seekingalpha.com

Starpharma to develop COVID-19 treatment
April 16, 2020 | seekingalpha.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.46 out of 5 stars

Medical Sector

1676th out of 2,016 stocks

Commercial Physical Research Industry

34th out of 42 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Starpharma.

2.3 Community Rank

Outperform Votes
Starpharma has received 32 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Starpharma has received 37 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Starpharma has received 53.62% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Starpharma and other stocks. Vote “Outperform” if you believe SPHRY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPHRY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Starpharma does not currently pay a dividend.
Dividend Growth
Starpharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Starpharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
Starpharma has a P/B Ratio of 26.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$15.00

-1.30 (-7.98 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SPHRY News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHRY and its competitors with MarketBeat's FREE daily newsletter.

Starpharma (OTCMKTS:SPHRY) Frequently Asked Questions

What stocks does MarketBeat like better than Starpharma?

Wall Street analysts have given Starpharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Starpharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Starpharma?

Starpharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 900 shares, an increase of 800.0% from the February 28th total of 100 shares. Based on an average daily trading volume, of 3,400 shares, the short-interest ratio is presently 0.3 days.
View Starpharma's Short Interest.

How has Starpharma's stock price been impacted by COVID-19 (Coronavirus)?

Starpharma's stock was trading at $6.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPHRY stock has increased by 141.2% and is now trading at $15.00.
View which stocks have been most impacted by COVID-19.

Who are Starpharma's key executives?

Starpharma's management team includes the following people:

Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 58)
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA, CFO & Company Sec.

Who are some of Starpharma's key competitors?

Some companies that are related to Starpharma include Precigen (PGEN), National Research (NRC), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Bioanalytical Systems (BASI), Auxly Cannabis Group (CBWTF), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Cleveland BioLabs (CBLI), Bioqual (BIOQ), ProMIS Neurosciences (ARFXF), NanoViricides (NNVC), AIkido Pharma (AIKI), Tenax Therapeutics (TENX) and Inhibitor Therapeutics (INTI).
View all of SPHRY's competitors.

What is Starpharma's stock symbol?

Starpharma trades on the OTCMKTS under the ticker symbol "SPHRY."

How do I buy shares of Starpharma?

Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Starpharma's stock price today?

One share of SPHRY stock can currently be purchased for approximately $15.00.

How much money does Starpharma make?

Starpharma has a market capitalization of $609.03 million and generates $4.40 million in revenue each year.

What is Starpharma's official website?

The official website for Starpharma is www.starpharma.com.

Where are Starpharma's headquarters?

Starpharma is headquartered at 4-6 Southampton Crescent, Abbotsford C3, 3072.

How can I contact Starpharma?

Starpharma's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Starpharma Stock Forecast, Price & News

Adding

Adding

Adding Starpharma Holdings Limited

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment